Cargando…

The development of activatable lytic peptides for targeting triple negative breast cancer

Cytolytic peptides are an emerging class of promising cancer therapeutics shown to overcome drug resistance. They eliminate cancer cells via disruption of the phospholipid bilayer of cell membranes, a mechanism that differentiates it from traditional treatments. However, applications of lytic peptid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Hui, Qin, Xuan, Yang, Dan, Jiang, Yanhong, Zheng, Weihao, Wang, Dongyuan, Tian, Yuan, Liu, Qisong, Xu, Naihan, Li, Zigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629628/ https://www.ncbi.nlm.nih.gov/pubmed/29263848 http://dx.doi.org/10.1038/cddiscovery.2017.37

Ejemplares similares

Stapling of unprotected helical peptides via photo-induced intramolecular thiol–yne hydrothiolation
por: Tian, Yuan, et al.
Publicado: (2016)

Integrated Design of a Membrane‐Lytic Peptide‐Based Intravenous Nanotherapeutic Suppresses Triple‐Negative Breast Cancer
por: Chen, Charles H., et al.
Publicado: (2022)

Achieving enhanced cell penetration of short conformationally constrained peptides through amphiphilicity tuning
por: Tian, Yuan, et al.
Publicado: (2017)

Acid‐Activatable Transmorphic Peptide‐Based Nanomaterials for Photodynamic Therapy
por: Sun, Bingbing, et al.
Publicado: (2020)

Activatable cell–biomaterial interfacing with photo-caged peptides
por: Lin, Yiyang, et al.
Publicado: (2018)

Activatable cell-penetrating peptides: 15 years of research
por: de Jong, Heleen, et al.
Publicado: (2020)

In Vivo Targeting of Hydrogen Peroxide by Activatable Cell-Penetrating Peptides
por: Weinstain, Roy, et al.
Publicado: (2013)

Development of CAPER peptides for the treatment of triple negative breast cancer
por: Chilewski, Shannon D., et al.
Publicado: (2020)

Peptide density targets and impedes triple negative breast cancer metastasis
por: Liu, Daxing, et al.
Publicado: (2018)

A Screened GPR1 Peptide Exerts Antitumor Effects on Triple-Negative Breast Cancer
por: Huang, Chen, et al.
Publicado: (2020)

Methodology of stable peptide based on propargylated sulfonium
por: Li, Heng, et al.
Publicado: (2023)

Immune-related biomarkers in triple-negative breast cancer
por: Zhang, Juan, et al.
Publicado: (2021)

X-ray-Activatable Photodynamic Nanoconstructs
por: Overchuk, Marta, et al.
Publicado: (2020)

Reversible stapling of unprotected peptides via chemoselective methionine bis-alkylation/dealkylation
por: Shi, Xiaodong, et al.
Publicado: (2018)

Activatable Peptides for Rapid and Simple Visualization of Protease Activity Secreted in Living Cells
por: Kim, Gae-Baik, et al.
Publicado: (2022)

Tuning of Peptide Cytotoxicity with Cell Penetrating Motif Activatable by Matrix Metalloproteinase-2
por: Lee, Jeonghun, et al.
Publicado: (2022)

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer
por: Lv, Mingming, et al.
Publicado: (2016)

Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells
por: Hossein-Nejad-Ariani, Hanieh, et al.
Publicado: (2019)

The Heparan Sulfate Binding Peptide in Tumor Progression of Triple-Negative Breast Cancer
por: Melo, Carina Mucciolo, et al.
Publicado: (2021)

Unlabeled aspirin as an activatable theranostic MRI agent for breast cancer
por: Pavuluri, KowsalyaDevi, et al.
Publicado: (2022)

Triple Negative Breast Cancer – An Overview
por: Aysola, Kartik, et al.
Publicado: (2013)

Recent advances of transcriptomics and proteomics in triple‐negative breast cancer prognosis assessment
por: Li, Yuan, et al.
Publicado: (2022)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

The tetrapeptide core of the carrier peptide Xentry is cell-penetrating: novel activatable forms of Xentry
por: Montrose, Kristopher, et al.
Publicado: (2014)

Ratiometric Activatable Cell-Penetrating Peptides Provide Rapid In Vivo Readout of Thrombin Activation**
por: Whitney, Michael, et al.
Publicado: (2013)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Huang, Yunxia, et al.
Publicado: (2023)

Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer
por: Yang, Yun-Yun, et al.
Publicado: (2021)

Oncolytic viruses for triple negative breast cancer and beyond
por: Jin, Shengye, et al.
Publicado: (2021)

Fibronectin-targeting and metalloproteinase-activatable smart imaging probe for fluorescence imaging and image-guided surgery of breast cancer
por: Cheng, Zhongquan, et al.
Publicado: (2023)

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
por: LIU, MIAO, et al.
Publicado: (2013)

Activatable Dendritic (19)F Probes for Enzyme Detection
por: Wang, Hui, et al.
Publicado: (2015)

Development of an immune-related prognostic biomarker for triple-negative breast cancer
por: Zhang, Yan, et al.
Publicado: (2022)

Identification of Five Cytotoxicity-Related Genes Involved in the Progression of Triple-Negative Breast Cancer
por: Zhang, Yan, et al.
Publicado: (2022)

Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer
por: Jiang, Lin, et al.
Publicado: (2022)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Molecular Imaging with Activatable Reporter Systems
por: Niu, Gang, et al.
Publicado: (2012)

InACTIVatINg cancer cachexia
por: Mathew, Sam J.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_293h92b1sr7n0ltafq36ve761i